Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one
2. Rpl 554
3. Rpl-554
4. Rpl554
1. Rpl-554
2. 298680-25-8
3. Rpl554
4. 1884461-72-6
5. Ensifentrine [inn]
6. Ensifentrine [usan]
7. Ls-193855
8. 3e3d8t1gix
9. Ls-193,855
10. A]isoquinolin-3(4h)-yl}ethyl)urea
11. (e)-1-(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]isoquinolin-3(4h)-yl)ethyl)urea
12. 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea
13. Trimethylphenyl)imino]-6,7-dihydro-2h-pyrimido[6,1-
14. N-(2-{(2e)-9,10-dimethoxy-4-oxo-2-[(2,4,6-
15. 2-(9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido(6,1-a)isoquinolin-3-yl)ethylurea
16. N-(2-((2e)-9,10-dimetoxi-4-oxo-2-((2,4,6-trimetilfenil)imino)-6,7-dihidro-2h-pirimido(6,1-a)isoquinolein-3(4h)-il)etil)urea
17. Urea, N-(2-(6,7-dihydro-9,10-dimethoxy-4-oxo-2-((2,4,6-trimethylphenyl)imino)-2h-pyrimido(6,1-a)isoquinolin-3(4h)-yl)ethyl)-
18. Unii-3e3d8t1gix
19. Vmx-554
20. Rpl-554;ensifentrinum
21. Ensifentrine (usan/inn)
22. Ensifentrine [who-dd]
23. Schembl625876
24. Chembl4594287
25. Schembl20720900
26. Gtpl11865
27. Dtxsid00183983
28. Bcp31840
29. Ex-a6633
30. Who 10726
31. Sb19810
32. D11743
33. A937318
34. Q7277486
35. Ensifentrina; Ensifentrinum;rpl-554;rpl554;rpl 554
36. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one
37. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one
38. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one
39. 9,10-dimethoxy-2-(2.4.6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6.1-a]isoquinolin-4-one
Molecular Weight | 477.6 g/mol |
---|---|
Molecular Formula | C26H31N5O4 |
XLogP3 | 2.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 477.23760449 g/mol |
Monoisotopic Mass | 477.23760449 g/mol |
Topological Polar Surface Area | 110 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 849 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...
About the Company : Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosyn...
About the Company : Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, inte...
About the Company : Chemicea Pharmaceuticals is a reputable contract research organization based in Pune, India. Specializing in chemistry-driven solutions, Chemicea offers a wide range of R&D product...
About the Company : Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With ...
Details:
Ohtuvayre (ensifentrine), is a first-in-class PDE3/4 inhibitor product candidate, which is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ohtuvayre
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Details : Ohtuvayre (ensifentrine), is a first-in-class PDE3/4 inhibitor product candidate, which is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease.
Brand Name : Ohtuvayre
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Oaktree Capital Management, L.P
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 09, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Oaktree Capital Management, L.P
Deal Size : $650.0 million
Deal Type : Financing
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Details : The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 09, 2024
Details:
The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Oxford Finance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Oxford Finance
Deal Size : Undisclosed
Deal Type : Financing
Details : The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 02, 2024
Details:
RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2023
Details:
RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2023
Details:
RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nuance Pharma Announces Dosing of First Patient in ENHANCE China Phase 3 Trial for COPD
Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 10, 2023
Details:
Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2023
Details:
Ensifentrine (RPL554) is an investigational, first-in-class, selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 that combines bronchodilator and anti-inflammatory activities in one compound.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ensifentrine (RPL554) is an investigational, first-in-class, selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 that combines bronchodilator and anti-inflammatory activities in one compound.
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2022
Details:
RPL554 (ensifentrine), met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RPL554 (ensifentrine), met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2...
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2022
Details:
The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine (RPL554), the first-in-class product candidate, which reported positive Phase 3 data in the ENHANCE-2 trial in chronic obstructive pulmonary disease.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Oxford Finance LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 17, 2022
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Oxford Finance LLC
Deal Size : Undisclosed
Deal Type : Financing
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
Details : The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine (RPL554), the first-in-class product candidate, which reported positive Phase 3 data in the ENHANCE-2 trial in chronic obstructi...
Brand Name : RPL554
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 17, 2022
RLD : Yes
TE Code :
Brand Name : OHTUVAYRE
Dosage Form : SUSPENSION;INHALATION
Dosage Strength : 3MG/2.5ML
Approval Date : 2024-06-26
Application Number : 217389
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-09-15
US Patent Number : 10945950
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217389
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-15
Patent Expiration Date : 2031-08-21
US Patent Number : 9062047
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 217389
Patent Use Code : U-3962
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-08-21
Patent Expiration Date : 2035-09-15
US Patent Number : 9956171
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217389
Patent Use Code : U-3962
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-15
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?